Webinar

Stirred & Shaken: Navigating Potential Disruptions at the U.S. National Institutes of Health

Available on-demand

60 Minutes

The Trump administration's abrupt implementation of a 15% cap on NIH indirect cost reimbursements—down from negotiated rates averaging 40–75%—has triggered a crisis across biomedical research and development. For biopharma, this $4 billion annual cut jeopardizes early-stage drug discovery programs, with SBIR/STTR grants (critical for small innovators) facing delays that could stall 37% of preclinical projects in infectious diseases and CNS therapies.

Medtech faces parallel disruption: DNA sequencing leaders like Illumina and PacBio saw immediate 7–14% stock drops as NIH-funded academic labs (44% of their customer base) face equipment budget freezes. The policy threatens to unwind collaborative ecosystems, with 80% of novel drug candidates originating from NIH-funded academic research. Indeed, 43% of 2025's Drugs to Watch™ candidates were underpinned by NIH-supported research.

This webinar will analyze cascading impacts including clinical trial suspensions, talent attrition, and risks to U.S. leadership in pandrug-resistant infections R&D. Panellists will examine the legal challenges from 22 states and institutional survival strategies alongside projections for therapeutic pipeline erosion through 2030.

Speakers

Dr. Hernan Bazan

Board-certified academic vascular surgeon and Program Director Ochsner Health and CEO of South Rampart Pharma

Dr. Hernan Bazan is a Board-certified academic vascular surgeon and Program Director of the Vascular Surgery Fellowship at Ochsner Health, as well as the CEO and co-founder of South Rampart Pharma. As the recipient of the 2024 NIH HEAL (Helping to End Addiction Long-term) Director’s Trailblazer Award, Dr. Bazan is well suited to discuss the significance of NIH funding in addressing critical issues of public health, such as the ongoing opioid crisis. Through his company, South Rampart Pharma, Dr. Bazan has developed a novel non-addictive pain killer, which would not have been possible without the support of the NIH, which funded its development. Dr. Bazan is a great resource of information regarding the NIH’s funding of translational science as well as its role in stimulating the economy by assisting small biotechnology companies.

Moira Ringo, PhD MBA

Principal US Pricing and Market Access Consulting

Clarivate

Moira comes to Clarivate with over 20 years of experience in healthcare industry and consulting, and focusses primarily on commercial strategy and market access. Her consulting roles include US and global clinical, market access, and HEOR evidence strategy for specialty drugs, diagnostics, medical devices, and cell and gene therapies. Her industry roles spanned research and development program leader to commercial lifecycle management and market access strategy. Moira is passionate about uniting diverse client and consulting teams around the common goal of bringing science and technology to patients who need it.

Matt Arnold

Principal Analyst

Clarivate

Matthew Arnold serves as a research analyst and content strategist. He joined Clarivate after covering the life science industries as a journalist for more than a decade and has followed pharmas and medtechs from the dawn of DTC advertising and mass-market blockbusters to the age of genetic medicine and surgical robotics.

Anette Breindl, PhD.

Managing Editor

BioWorld Science

Anette Breindl, PhD, is the managing editor for BioWorld Science, an award-winning science writer, and the co-author of several peer-reviewed publications. She has worked in science communications since obtaining her PhD in 1999. As the beneficiary of undergraduate and graduate research fellowships by the National Science Foundation and its German equivalent, the Deutsche Forschungsgemeinschaft.

Register here to watch on-demand!

Already registered? Click here to login.